Chemotherapy-Induced Nausea and Vomiting: Assessing Patients and Nurses' Knowledge, Attitudes, and Practices in Clinical Settings Across North Kerala
DOI:
https://doi.org/10.5530/ajphs.2025.15.86Keywords:
Chemotherapy, Knowledge, Nurses, AttitudeAbstract
Background: Chemotherapy-Induced Nausea and Vomiting (CINV) remains an important concern in cancer care and treatment despite existing guidelines and management to relieve discomfort and preserve a patient's quality of life during chemotherapy. Understanding the knowledge, attitudes, and practices (KAP) of both nurses and patients can reveal gaps and discrepancies in the management of CINV. Objectives: To assess KAPconcerning chemotherapy-induced nausea and vomiting (CINV) among nurses and patients according to nurses and patients living in North Kerala, India, and determine what factors influenced their KAP. Methods: A cross-sectional survey was developed and utilized to understand KAP related to CINV from February 2024 to May 2024, with 910 participants (404 nurses and 514 patients) using a validated KAP questionnaire. Demographic correlations were statistically analyzed. Results: Factors associated with knowledge and practices included older age, male gender, higher education, and more years of work experience. Nurses demonstrated good knowledge about emetogenic agents (82%) and sequential reporting of CINV symptoms (64%), but understanding of CINV definitions (45%) and non-pharmacologic management approaches (47%) was poor. Patients in this study actively sought information (90%) and reported symptoms (85%), but only 30% consulted healthcare providers before using antiemetics. A majority (74%) of nurses also felt that their peers overlooked the importance of reporting chemotherapy symptomatology. Conclusion: Nurses and patients demonstrated a solid understanding of the pharmacologic management of CINV, but lacked a good experience or awareness of non-drug and documentation procedures. Education, systemic protocol, mentorship, and patient-centered communication are required to improve the reporting of symptoms associated with CINV amongst patients.
References
Aapro, M., Molassiotis, A., Roila, F., et al. (2022). Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting. European Journal of Cancer, 166, 126–133. https://doi.org/10.1016/j.ejca.2022.01.012
Borison, H. L. (1989). Area postrema: Chemoreceptor circumventricular organ of the medulla oblongata. Progress in Neurobiology, 32(5), 351–390. https://doi.org/10.1016/0301-0082(89)90028-2
Carpenter, D. O. (1990). Neural mechanisms of emesis. Canadian Journal of Physiology and Pharmacology, 68(2), 230–236. https://doi.org/10.1139/y90-036
Cohen, L., De Moor, C.A., Eisenberg, P., Ming, E. E., & Hu, H. (2007). Chemotherapy-induced nausea and vomiting—Incidence and impact on patient quality of life at community oncology settings. Supportive Care in Cancer, 15(5), 497–503. https://doi.org/10.1007/s00520-006-0173-z
Dacey, M. L., Kennedy, M. A., & Polakowski, C. B. (2013). The impact of lifestyle medicine continuing education on provider knowledge, attitudes, and counseling behaviors. Medical Teacher, 35(5), e1149–e1156. https://doi.org/10.3109/0142159X.2012.733459
De Boer-Dennert, M., de Wit, R., Schmitz, P. I. M., Djontono, J., Beurden, V., Stoter, G., & Verweij, J. (1997). Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. British Journal of Cancer, 76(8), 1055–1061. https://www.nature.com/articles/bjc1997507
Di Renzo, N., Montagnese, C., Ruberto, C., Graziano, C., & Cosentino, G. (2011). Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin’s lymphoma. Supportive Care in Cancer, 19(10), 1505–1510. https://doi.org/10.1007/s00520-010-0974-y
Fernández-Ortega, P., Caloto, M. T., Chirveches, E., Marquilles, R., Nuñez, M., Muñoz, M., & Suárez, C. (2012). Chemotherapy-induced nausea and vomiting in clinical practice: Impact on patients’ quality of life. Supportive Care in Cancer, 20(12), 3141–3148. https://doi.org/10.1007/s00520-012-1448-1
Gebre, D., Kebede, E., & Bewket, B. (2022). Knowledge, practice and perceived barriers of nurses on management of chemotherapy-induced nausea and vomiting. BMC Nursing, 21(1), 223. https://doi.org/10.1186/s12912-022-01009-7
Griffin, A. M., Butow, P. N., Coates, A. S., Childs, A. M., Ellis, P. M., Dunn, S. M., & Tattersall, M. H. N. (1996). On the receiving end V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Annals of Oncology, 7(2), 189–195. https://doi.org/10.1093/oxfordjournals.annonc.a010523
Gupta, K., Walton, R., & Kataria, S. P. (2021). Chemotherapy-induced nausea and vomiting: Pathogenesis, recommendations, and new trends. Cancer Treatment and Research Communications, 26, 100278. https://doi.org/10.1016/j.ctarc.2020.100278
Hesketh, P. J., Aapro, M., Street, J. C., & Carides, A. D. (2012). Prospective evaluation of the incidence of delayed nausea and vomiting in participants with colorectal cancer receiving oxaliplatin-based chemotherapy. Supportive Care in Cancer, 20(5), 1043–1047. https://doi.org/10.1007/s00520-011-1180-2
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., … & Roila, F. (2017). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 35(28), 3240–3261. https://doi.org/10.1200/JCO.2017.74.4789
Janelsins, M. C., Tejani, M. A., Kamen, C. S., Peoples, A. R., Mustian, K. M., & Morrow, G. R. (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opinion on Pharmacotherapy, 14(6), 757–766. https://doi.org/10.1517/14656566.2013.776541
Kris, M. G., Tyson, L. B., Gralla, R. J., Clark, R. A., & Cirrincione, C. (1985). Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Journal of Clinical Oncology, 3(10), 1379–1384. https://doi.10.1200/JCO.1985.3.10.1379
Krishnasamy, M., Wilkie, E., & Crowe, S. (2014). The nurse’s role in managing chemotherapy-induced nausea and vomiting: An international survey. Cancer Nursing, 37(4), E27–E35. https://doi.org/10.1097/NCC.0000000000000012
Mitchelson, F. (1992). Pharmacological agents affecting emesis: A review (Part I). Drugs, 43(3), 295–315. https://doi.org/10.2165/00003495-199243030-00002
Morrow, G. R., Rosenthal, S. N., Hickok, J. T., Stern, R. M., & Andrews, P. L. R. (1998). Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Supportive Care in Cancer, 6(3), 244–247. https://doi.org/10.1007/s005200050161
Tavorath, R., & Hesketh, P. J. (1996). Drug treatment of chemotherapy-induced delayed emesis. Drugs, 52(5), 639–648. https://doi.org/10.2165/00003495-199652050-00002
Todaro, B. (2012). Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. Journal of the National Comprehensive Cancer Network, 10(4), 487–492. https://doi.org/10.6004/jnccn.2012.0048
Van Laar, E. S., Desai, J. M., & Jatoi, A. (2015). Professional educational needs for chemotherapy-induced nausea and vomiting (CINV). Supportive Care in Cancer, 23(1), 151–157. https://doi.org/10.1007/s00520-014-2325-x.
